生物制药公司Apogee Therapeutics近日披露了其核心候选药物Zumilokibart（研发代号APG777）在轻中度哮喘患者中开展的1B期临床试验的中期分析数据，结果显示出积极信号。该抗体药物靶向IL-13通路，被公司定位为潜在“同类最佳”疗法。
与此同时，Apogee还明确了2026年的关键研发节点与战略展望，为后续临床推进和商业化布局奠定基础。
生物制药公司Apogee Therapeutics近日披露了其核心候选药物Zumilokibart（研发代号APG777）在轻中度哮喘患者中开展的1B期临床试验的中期分析数据，结果显示出积极信号。该抗体药物靶向IL-13通路，被公司定位为潜在“同类最佳”疗法。
与此同时，Apogee还明确了2026年的关键研发节点与战略展望，为后续临床推进和商业化布局奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.